Acadia Lifts Daybue Sales Forecast To $505–$520 Million After Rett Drug Jumps 39%

The drugmaker narrowed its total revenue range while third-quarter net income fell to $54 million from $72 million.

Share
Acadia Lifts Daybue Sales Forecast To $505–$520 Million After Rett Drug Jumps 39%

Acadia Pharmaceuticals, which develops drugs for neurological and rare diseases, raised its 2026 sales forecast for Rett syndrome drug Daybue to $505 million to $520 million, up from $480 million to $510 million. The company announced the increase Wednesday with third-quarter results, in which Daybue sales climbed 39% from a year earlier.

Daybue leads a $342 million quarter

Daybue net sales were $140 million in the third quarter, against $101 million a year earlier. The company credited strong uptake of Daybue STIX, a newer form of the drug.

Total revenue was $342 million, up 23% from $279 million in the third quarter of 2025, or 22% against an adjusted year-earlier figure of $281 million. Nuplazid, approved for hallucinations and delusions tied to Parkinson's disease psychosis, brought in $202 million, up 14% as reported and 12% against an adjusted $180 million. The adjustment strips out a change in estimate for Medicare rebate accruals.

CEO Catherine Owen Adams said Daybue "delivered another strong quarter." She also pointed to the launch of Daybu, the European name for the drug, in Germany in early October, with patients already receiving commercial product.

Profit slips as selling costs climb

Net income fell to $54 million, or $0.31 per diluted share, from $72 million, or $0.42, a year earlier. Selling, general and administrative expenses rose to $159 million from $133 million. Research spending fell to $76 million from $88 million.

The prior-year quarter also included an income tax benefit; this quarter carried a tax expense of about $27 million.

Full-year guidance now reads:

  • Total revenue: $1.265 billion to $1.295 billion, from $1.24 billion to $1.30 billion.
  • Nuplazid sales: $760 million to $775 million, from $760 million to $790 million.
  • Research and development spending: $325 million to $340 million, from $355 million to $380 million.
  • Selling, general and administrative spending: $665 million to $685 million, from $660 million to $700 million.

Cash and investment securities reached $976 million at September 30, from $820 million at the end of 2025.

Pipeline readouts in 2027

Acadia will present more data from its Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis at a conference in Boston on November 17. The company said the topline results showed consistent efficacy trends at the 60 mg dose and supported continued Phase 3 development.

It expects two mid-stage readouts in 2027: ACP-211 in major depression in the second half, and remlifanserin in Lewy body dementia psychosis in the fourth quarter. The FDA granted Fast Track designation, a status meant to speed review, for remlifanserin in the latter condition.

Acadia also received a new US patent allowance covering weight-banded dosing of trofinetide, Daybue's active ingredient. It extends protection for Daybue and Daybue STIX through March 2041.

Acadia's remlifanserin data goes before the Clinical Trials on Alzheimer's Disease conference in Boston on November 17.

Sources

More on Acadia Pharmaceuticals

All Acadia Pharmaceuticals (ACAD) coverage →